Memantine Hydrochloride And Donepezil Hydrochloride Capsule, Extended Release
Product Images NDC 69680-183

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride And Donepezil Hydrochloride (NDC 69680-183). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vitruvias Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel – 14/10 mg Bottle (Label 14mg)

Label for memantine hydrochloride and donepezil hydrochloride extended-release capsules, strength 14 mg/10 mg per capsule. The label indicates 30 capsules per container, prescription use only. It includes manufacturer information for Xiamen LP Pharmaceutical Co., Ltd., China, and distributor Vitruvias Therapeutics, Inc., Auburn, AL, USA. Storage instructions and dosage guidance are partially visible.*

FDA Label Image

Principal Display Panel – 28/10 mg Bottle (Label 28mg)

Label for Memantine and Donepezil Hydrochlorides Extended-Release Capsules, dosed at 28 mg/10 mg per capsule. The label indicates a package size of 30 capsules, with the product manufactured by Xiamen LP Pharmaceutical Co., Ltd. in China and distributed by Vitruvias Therapeutics in Auburn, AL. The label includes storage instructions and dosage details with a barcode and a QR code area.*

FDA Label Image

Memantine Hydrochloride Structural Formula (Memantine And Donepezil Hydrochlorides 1)

Chemical structure of memantine hydrochloride. The diagram shows the molecular arrangement of atoms including nitrogen (NH2) and hydrochloride (HCl) groups attached to the cage-like adamantane framework with methyl (CH3) groups.*

FDA Label Image

Figure 8 (Memantine And Donepezil Hydrochlorides 10)

A cumulative percentage graph showing ADCS-ADL (Alzheimer's Disease Cooperative Study–Activities of Daily Living) change from baseline. The chart compares donepezil hydrochloride 10 mg/day and placebo groups, plotting cumulative percentage of patients against changes in ADCS-ADL scores, with distinct curves for each group.*

FDA Label Image

Donepezil Hydrochloride Structural Formula (Memantine And Donepezil Hydrochlorides 2)

Chemical structure of memantine hydrochloride, shown as a molecular diagram with labeled atoms and bonds, illustrating the compound's chemical composition.*

FDA Label Image

Figure 1 (Memantine And Donepezil Hydrochlorides 3)

A line graph showing mean change from baseline in SIS scores over 24 weeks of treatment comparing Memantine HCl ER 28 mg/AChEI and placebo/AChEI. The graph illustrates clinical improvement and decline, with treatment weeks on the x-axis and mean change scores on the y-axis, including error bars representing SEM.*

FDA Label Image

Figure 2 (Memantine And Donepezil Hydrochlorides 4)

A cumulative percentage of patients chart showing the SIB change from baseline on the x-axis and cumulative percentage of patients on the y-axis. Two curves are presented: one for Memantine HCl ER 28 mg combined with AChEI and another for Placebo combined with AChEI, illustrating patient response distributions over a range of SIB change values.*

FDA Label Image

Figure 3 (Memantine And Donepezil Hydrochlorides 5)

A line graph depicting mean CIBIC-Plus scores (± SEM) over 24 weeks of treatment comparing memantine hydrochloride extended release 28 mg/acetylcholinesterase inhibitor (AChEI) versus placebo/AChEI. The y-axis shows CIBIC-Plus scores indicating clinical improvement or decline, and the x-axis shows weeks of treatment. Memantine shows a trend towards clinical improvement compared to placebo over time.*

FDA Label Image

Figure 4 (Memantine And Donepezil Hydrochlorides 6)

A bar chart comparing percentage of patients by CIBIC-Plus Rating between two groups: Memantine HCl ER 28 mg/AChEI versus Placebo/AChEI. Ratings range from Marked Improvement to Marked Worsening, with most patients showing No Change in both groups.*

FDA Label Image

Figure 5 (Memantine And Donepezil Hydrochlorides 7)

Line graph showing SIB change from baseline (mean ± SE) over 6 months of drug treatment comparing donepezil hydrochloride 10 mg/day and placebo. The donepezil group shows clinical improvement with positive change, while the placebo group trends toward clinical decline with negative change.*

FDA Label Image

Figure 6 (Memantine And Donepezil Hydrochlorides 8)

A cumulative percentage curve graph comparing donepezil hydrochloride 10 mg/day to placebo in terms of SIB (Severe Impairment Battery) change from baseline. The x-axis shows SIB change values ranging from approximately +30 to -75, and the y-axis shows cumulative percentage of patients from 0% to 100%. Donepezil demonstrates a steeper cumulative increase at negative SIB change values compared to placebo.*

FDA Label Image

Figure 7 (Memantine And Donepezil Hydrochlorides 9)

A line graph depicting the mean ADCS-ADL change from baseline over 6 months of drug treatment comparing donepezil hydrochloride 10 mg/day and placebo. The vertical axis shows change from baseline, ranging from clinical improvement to clinical decline, and the horizontal axis indicates months of treatment. Donepezil shows less decline compared to placebo over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.